Welcome to our dedicated page for GERRESHEIMER ORD news (Ticker: GRRMF), a resource for investors and traders seeking the latest updates and insights on GERRESHEIMER ORD stock.
Gerresheimer AG ORD (GRRMF) is an innovative provider of systems and solutions for the pharma and biotech industries. With a focus on medical systems like syringes, pens, and auto-injectors, Gerresheimer has seen strong organic revenue growth and profitability. The company offers a broad range of solutions for biopharmaceuticals and is expanding its production capacities globally to meet growing demand.
Gerresheimer AG reported a strong start to 2021, achieving revenues of EUR 303 million in Q1, a 3.1% increase year-on-year. Growth was driven by the Plastics & Devices Division, with a notable demand for syringes and pharmaceutical packaging. Adjusted EBITDA rose to EUR 54 million, reflecting a 29.3% year-on-year increase in adjusted earnings per share at EUR 0.57. The company forecasts mid single-digit revenue growth for 2021 and aims for an adjusted EBITDA margin of 22-23%. Gerresheimer is expanding production for Covid-19 vaccine vials, reinforcing its role in the pandemic response.
FAQ
What is the market cap of GERRESHEIMER ORD (GRRMF)?
What is Gerresheimer AG ORD known for?
What are some of Gerresheimer's key products?
How is Gerresheimer expanding its operations?
What has been Gerresheimer's revenue growth like?
Who is the CEO of Gerresheimer AG?
What is Gerresheimer's outlook for the future?
Where can I find the Half-Year Financial Report of Gerresheimer?
How many production sites does Gerresheimer have globally?
What is the revenue of Gerresheimer in 2022?
In which stock exchange is Gerresheimer AG listed?
